The legacy of Viagra and its originator, copyright, presents a fascinating picture for cautious investors. While the iconic drug initially fueled enormous earnings, its patent has lapsed , leading to rival options flooding the market . This erosion in value presents a substantial hurdle for copyright and any fund considering a large holding in the